Archives
-
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-10-10
Grafton et al. developed a phenotypic screening framework that combines induced pluripotent stem cell-derived cardiomyocytes with high-content imaging and deep learning. Screening known bioactive compounds and chemically diverse molecules revealed cardiotoxicity-associated patterns across several pharmacological classes, while also highlighting the need for orthogonal validation before translating image-based signals into mechanistic or clinical conclusions.
-
Leucomycin (Kitasamycin): Mechanism and Evidence
2026-10-09
Leucomycin, also called kitasamycin, is a multicomponent 16-membered macrolide antibiotic complex. Its strongest evidence base concerns ribosome-mediated translational inhibition and component-specific biosynthesis, while product-page activity claims require strain- and assay-specific validation.
-
Reserpine N1867: Product Overview
2026-10-09
Reserpine N1867 is an APExBIO-listed research compound with catalog-reported identity, purity, and intended neuropharmacology applications. No matched paper evidence was supplied, so biological performance and mechanism claims remain unverified.
-
EZ Cap Cy5 Firefly Luciferase mRNA: Evidence Overview
2026-10-08
A source-grounded overview of EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP), its dual-reporter rationale, relevance to mRNA delivery and transfection research, and the limitations of current evidence.
-
Bafilomycin A1: Evidence in Cell Biology Research
2026-10-08
Bafilomycin A1 is commonly used as a pharmacological probe of vacuolar H+-ATPase function, intracellular pH regulation, and lysosomal biology. Evidence from a grass carp reovirus entry study illustrates both its value and its limits: a negative result with bafilomycin A1 did not exclude a role for endosomal acidification, underscoring the need to distinguish target-specific evidence from broader pharmacological effects.
-
SW033291 and 15-PGDH Inhibition: Evidence Overview
2026-10-07
SW033291 is a research small molecule associated with 15-PGDH inhibition and prostaglandin E2 biology. This overview separates supplier-reported assay characteristics from a 2026 PNAS mouse study of 15-PGDH inhibition during semaglutide-associated weight loss. It examines implications for muscle repair, hematopoietic stem cell expansion, and tissue regeneration research while emphasizing that the published muscle findings do not establish clinical efficacy or directly validate SW033291 as the compound used.
-
DAPT (GSI-IX): Evidence in Human Neurons
2026-10-07
DAPT, also known as GSI-IX, is a research tool used to interrogate γ-secretase-dependent biology, including APP processing and the Notch signaling pathway. The supplied 2025 mBio study validates a human induced-pluripotent-stem-cell-derived sensory neuron model for HSV-1 latency, but it does not establish DAPT as an antiviral, latency-modifying, or therapeutic agent; any connection between γ-secretase inhibition and this model remains a research question.
-
Kidney-Targeted mRNA Nanoparticles: Study Insights
2026-10-06
A 2024 Pace University dissertation examined whether excipients could address a payload-saturation problem in polymeric mesoscale nanoparticles intended for kidney-targeted mRNA delivery. The work connected loading measurements with particle size, cytotoxicity, cellular uptake, pharmacokinetics, and reporter-protein readouts, while also highlighting the limits of interpreting formulation performance from a single dissertation-scale study.
-
SW033291: Rethinking 15-PGDH in Muscle Repair
2026-10-06
A source-grounded perspective on SW033291, 15-PGDH inhibition, and the emerging link between prostaglandin E2 biology, muscle regeneration, hematopoiesis, and translational strategy.
-
Merbromin as a Mixed-Type Inhibitor of SARS-CoV-2 3CLpro
2026-10-05
Chen et al. identified merbromin as a selective, mixed-type inhibitor of the SARS-CoV-2 main protease 3CLpro through biochemical screening of approximately 6,000 compounds. Kinetic, binding, and docking evidence supports a multi-site inhibition model, while the absence of comparable inhibition against three unrelated proteases highlights selectivity within the tested system rather than clinical efficacy.
-
APEX2 Supports TERT Expression in Human Stem Cells
2026-10-05
A 2024 bioRxiv preprint reports that APEX2, but not its paralog APEX1, is needed for efficient TERT expression and telomerase activity in human embryonic stem cells. The study links APEX2 occupancy near repetitive DNA within the TERT locus to a possible DNA repair–dependent layer of transcriptional control, while emphasizing that the mechanism remains to be established.
-
Blue Light, EGFR Signaling, and Skin Barrier Damage
2026-10-04
A 2026 Journal of Investigative Dermatology study combines human, mouse, imaging, histologic, and mechanistic evidence to show that repeated blue-light exposure is associated with persistent skin-barrier impairment. Its central contribution is linking these structural and functional changes to the EGFR/ERK/c-Jun signaling axis while highlighting important limits in exposure relevance and pathway specificity.
-
How a Lipidated Nanophotosensitizer Disables Tumor EVs
2026-10-03
A 2025 Nature Cancer study developed a palmitic-acid-displayed nanophotosensitizer that accumulates in tumor cells and tumor extracellular vesicles, enabling synchronized photodynamic damage to both compartments. The findings support a preclinical strategy for suppressing primary tumors while disrupting vesicle-mediated communication associated with metastasis, although clinical applicability and tumor selectivity remain unresolved.
-
CCR5-Containing EVs in Rheumatoid Arthritis
2026-10-02
This study identifies CCR5-bearing extracellular vesicles from rheumatoid arthritis synovial fibroblasts as active mediators of cartilage destruction and bone erosion. Using human cell experiments and an adjuvant-induced arthritis rat model, it shows that removing or pharmacologically blocking CCR5 can reduce EV-associated inflammatory signaling and joint damage.
-
AMPK–p62 Feedback Under Metabolic Stress
2026-10-01
The 2024 AUTOPHAGY study identifies a double-positive feedback loop in which AMPK and SQSTM1/p62 reinforce one another during metabolic stress. This circuit coordinates lysosomal stress sensing, KEAP1 degradation, NRF2 activation, and antioxidant adaptation, providing a mechanistic explanation for how STK11/LKB1- and KEAP1-altered lung cancer cells may survive nutrient limitation.